Perioperative chemotherapy or preoperative chemoradiotherapy in esophageal cancer

J Hoeppner, T Brunner, C Schmoor… - … England Journal of …, 2025 - Mass Medical Soc
Background The best multimodal approach for resectable locally advanced esophageal
adenocarcinoma is unclear. An important question is whether perioperative chemotherapy is …

Unraveling the tumor microenvironment of esophageal squamous cell carcinoma through single-cell sequencing: A comprehensive review

L Qi, J Wang, S Hou, S Liu, Q Zhang, S Zhu… - … et Biophysica Acta (BBA …, 2025 - Elsevier
Esophageal squamous cell carcinoma (ESCC) is a highly heterogeneous and aggressive
malignancy. The progression, invasiveness, and metastatic potential of ESCC are shaped …

Textbook Neoadjuvant Outcome—Novel Composite Measure of Oncological Outcomes among Gastric Cancer Patients Undergoing Multimodal Treatment

Z Pelc, K Sędłak, M Leśniewska, K Mielniczek… - Cancers, 2024 - mdpi.com
Simple Summary This narrative review aims to present the rationale for the implementation
of a novel composite measure, Textbook Neoadjuvant Outcome, among patients with gastric …

Impact of the interval between neoadjuvant immunotherapy and surgery on prognosis in esophageal squamous cell carcinoma (ESCC): a real-world study

G Yang, Y Hong, X Zhang, C Zeng, L Tan… - Cancer Immunology …, 2024 - Springer
Background The time interval between neoadjuvant immunotherapy and surgery is 6 weeks
for esophageal squamous cell carcinoma (ESCC), but whether delayed surgery affects …

Outcomes of salvage surgery for esophageal carcinoma: a nationwide cohort study from the Dutch upper GI cancer audit

MR Visser, DM Voeten, SS Gisbertz, JP Ruurda… - Annals of Surgical …, 2024 - Springer
Background Salvage esophagectomy is more complex and associated with higher
postoperative morbidity and mortality than standard resection. This study aimed to …

Optimal time-to-surgery recommendations based on primary tumor volume regression for patients with resectable esophageal cancer after neoadjuvant …

J Li, X Zhou, Y Liu, J Zhu, G Wan, Y Wang… - Annals of Surgical …, 2024 - Springer
Background Neoadjuvant chemoradiotherapy (NCRT) has shown promise in improving the
prognosis of individuals with locally advanced esophageal squamous cell carcinoma (LA …

Prolonged time to surgery in patients with residual disease after neoadjuvant chemoradiotherapy for esophageal cancer

HCG Overtoom, BM Eyck, BJ Van Der Wilk… - Annals of …, 2024 - journals.lww.com
Objective: To investigate whether prolonged time to surgery negatively affects survival,
pathological outcome or postoperative complications in patients with histologically proven …

Factors influencing pathological complete response and tumor regression in neoadjuvant radiotherapy and chemotherapy for high-risk breast cancer

J Haussmann, W Budach, C Nestle-Krämling… - Radiation …, 2024 - Springer
Background Pathological complete response (pCR) is a well-established prognostic factor in
breast cancer treated with neoadjuvant systemic therapy (naST). The determining factors of …

[HTML][HTML] Impact of Preoperative Time Intervals for Neoadjuvant Chemoradiotherapy on Short-term Postoperative Outcomes of Esophageal Cancer Surgery: A …

J Wang, C de Jongh, Z Wu, EM de Groot… - Annals of …, 2024 - journals.lww.com
Objective: To clarify the impact of the preoperative time intervals on short-term postoperative
and pathologic outcomes in patients with esophageal cancer who underwent neoadjuvant …

Top advances of the year: Gastroesophageal cancer

KA Goodman, A Hotca, M Liu, VE Strong, DH Ilson - Cancer, 2024 - Wiley Online Library
Top advances of the year: Gastroesophageal cancer - Goodman - 2024 - Cancer - Wiley Online
Library Skip to Article Content Skip to Article Information American Cancer Society Journals …